News Releases

Our latest news, announcements and multimedia resources

Latest News

November 7, 2024

Canada’s Drug Agency Recommends WINREVAIR^® (sotatercept) for Reimbursement

October 30, 2024

Merck Canada Marks Health Literacy Month by Publishing a Roundtable Report on Immunization

September 12, 2024

Health Canada Approves KEYTRUDA^® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options

September 5, 2024

Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG^® (belzutifan)

September 4, 2024

WINREVAIR^® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension

August 30, 2024

David D. Jones is appointed as President and Managing Director of Merck Canada

August 22, 2024

Health Canada Approves KEYTRUDA^® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination with enfortumab vedotin

July 16, 2024

Health Canada Approves CAPVAXIVE^®, (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease in Adults

June 19, 2024

MERCK CANADA ENCOURAGES CANADIANS TO PRACTICE SKINTIMACY^™

May 09, 2024

Health Canada Approves KEYTRUDA^® for Adult Patients with Locally Advanced Unresectable or Metastatic Biliary Tract Carcinoma, in Combination with Gemcitabine-Based

April 19, 2024

Health Canada Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

April 19, 2024

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

March 05, 2024

Merck Canada Launches Indigenous Student Scholarship

February 15, 2024

Merck Canada and the Centre for Vaccine Preventable Diseases (CVPD) Relaunch Collaboration to Advance Vaccine Research and Education

February 12, 2024

Health Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumours express PD-L1 (CPS ≥ 1)

February 8, 2024

Merck Canada Announces Collaboration with Vector Institute to Further Advance its Artificial Intelligence Capabilities and Drive Innovation in Healthcare

December 21, 2023

KEYTRUDA^® (pembrolizumab) Plus LENVIMA^® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR

November 1, 2023

Hayley Wickenheiser and Merck Canada Face-Off Against Lung Cancer

October 25, 2023

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) is Available for the First-LineTreatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

August 2, 2023

Lung Diagnostic Assessment Program Outreach Clinic in Napanee, ON Expedites Assessment and Diagnosis for Patients with Lung Cancer

June 21, 2023

Melanoma is on the rise in Canada but there are ways to take action this summer

June 13, 2023

Merck Canada’s Executive Director, Legal and Compliance & Chief Privacy Officer, Chantal Desbiens, honoured at the Canadian General Counsel Awards with Litigation Management award

November 26, 2021

Kingston Health Sciences Centre Expands Lung Diagnostic Assessment Program to Napanee, ON

Corporate News

July 16, 2024

Health Canada Approves CAPVAXIVE^®, (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease in Adults

April 19, 2024

Health Canada Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

April 19, 2024

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

March 05, 2024

Merck Canada Launches Indigenous Student Scholarship

February 15, 2024

Merck Canada and the Centre for Vaccine Preventable Diseases (CVPD) Relaunch Collaboration to Advance Vaccine Research and Education

February 8, 2024

Merck Canada Announces Collaboration with Vector Institute to Further Advance its Artificial Intelligence Capabilities and Drive Innovation in Healthcare

August 2, 2023

Lung Diagnostic Assessment Program Outreach Clinic in Napanee, ON Expedites Assessment and Diagnosis for Patients with Lung Cancer

June 21, 2023

Melanoma is on the rise in Canada but there are ways to take action this summer

June 13, 2023

Merck Canada’s Executive Director, Legal and Compliance & Chief Privacy Officer, Chantal Desbiens, honoured at the Canadian General Counsel Awards with Litigation Management award

November 26, 2021

Kingston Health Sciences Centre Expands Lung Diagnostic Assessment Program to Napanee, ON

November 8, 2021

Merck Canada and Guy Lafleur Team Up Against Lung Cancer

September 13, 2021

Marwan Akar Appointed as President & Managing Director of Merck Canada

Product News

February 12, 2024

Health Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumours express PD-L1 (CPS ≥ 1)

December 21, 2023

KEYTRUDA^® (pembrolizumab) Plus LENVIMA^® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR

October 25, 2023

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) is Available for the First-LineTreatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Contact Our Media Team

This information is intended for media professionals only.

To ensure that customers, investors, and others receive the appropriate attention, Merck Canada media contacts may ONLY respond to calls and emails from professional journalists.

If you are a member of the media and would like to contact our media relations staff about Merck Canada, please use the email address below.General Media information: mediacanada@merck.com

This webpage is designed to provide members of the media with quick and easy access to recent information about Merck Canada. For more information about Merck Canada, please visit the Our Company page.